BHVN Biohaven Future Price to Earnings
High promotion costs and patent protection create significant barriers to entry for new players in neuropharmaceuticals. The forward P/E dynamics of Biohaven Ltd. demonstrate resilience, with the metric currently standing at 0.00. The efficiency of Biohaven Ltd. is based on bioinformatic automation of formula discovery, enabling the company to compete successfully with industry behemoths for priority in the registration of innovative drugs.
Analytical breakdowns for Biohaven Corp (BHVN)
- stock quotes and analyst forecast:
- market capitalization data:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Biohaven Ltd.|BHVN - Long-Term Debt to Equity|Short-Term Debt to Capital Biohaven Ltd.|BHVN - Company Cumulative Debt|Debt to Book Capitalization Ratio Biohaven Ltd|BHVN - Company Long-Term Indebtedness|Company Current Liabilities Biohaven|Quick Liquidity biohavenpharma.com
- earnings and market ratios statistics:
BHVN - Company Net Income|Future Profit Biohaven Ltd.|BHVN - Market Price to Net Income Ratio|Forward P/E Multiple Biohaven Pharmaceutical|BHVN - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Biohaven Ltd|BHVN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Biohaven|BHVN - Earnings per share for the last twelve months|Quarterly EPS earnings growth biohavenpharma.com|BHVN - Earnings per share increase in current year|Expected earnings per share growth for next year Biohaven Ltd.
Analysis of all company metrics:BHVN Biohaven
Forward P/E determines the investment payback period based on expected earnings. By analyzing the forward P/E history of Biohaven Ltd. (BHVN), an investor can track the dynamics of risk valuation. This metric correlates the current share price with the projected earnings per share. A declining multiple may signal asset degradation. For Biohaven Ltd. (BHVN), this calculation is critical, as the lack of stable revenue and dependence on clinical trials render forecasts volatile.
Who Biohaven Ltd. competes with
Forward P/E Multiple BIIB|Market Cap to Projected Earnings Neurocrine|Future Price to Earnings Regencell RGC|Axsome Corp (AXSM) - Projected Price to Earnings Ratio|ACADIA Pharmaceuticals - Forward P/E Multiple|Future Price to Earnings Multiple XENE (xenon-pharma.com)|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Forward P/E Multiple|Projected Price to Earnings CPRX|Future Price to Earnings DNLI|Forward P/E Multiple HRMY|AMLX - Projected Price to Earnings Ratio|Future Price to Earnings Trevi Therapeutics, Inc. TRVI|PRAX: Price to Future Earnings Ratio|AVXL: Projected Price to Earnings|Future Price to Earnings Multiple CBLL (CeriBell EEG)|prothena.com (PRTA) - Future Price to Earnings|ALEC (Alector) - Future Price to Earnings|Projected Price to Earnings ANNX|OMER (Omeros Corp.) - Market Cap to Future Earnings Ratio|Forward P/E Multiple NGNE|AC Immune Inc - Price to Future Earnings Ratio|Voyager Therapeutics - Projected Price to Earnings|Market Cap to Projected Earnings neumoratx.com (NMRA)|Scilex - Forward P/E Multiple|TVGN: Future Price to Earnings|ACOG: Forward P/E Multiple|Cognition Therapeutics Inc. - Future Price to Earnings Multiple|Projected Price to Earnings IKT|Future Price to Earnings SAVA|Future Price to Earnings Assertio Holdings, Inc. (ASRT)|coyatherapeutics.com - Price to Future Earnings Ratio|Future Price to Earnings Vistagen VTGN|OVID: Price to Future Earnings Ratio|Acumen Pharmaceuticals - Forward P/E Multiple|Projected Price to Earnings Ratio cervomed.com|ATHE (alteritytherapeutics.com) - Projected Price to Earnings|Clene (CLNN) - Forward P/E Multiple|Future Price to Earnings PepGen Inc|JUNS: Future Price to Earnings Multiple|Future Price to Earnings Relmada Therapeutics (RLMD)|ANVS - Projected Price to Earnings Ratio|Forward P/E Multiple GRCE (Grace Therapeutics)|Firefly Neuroscience, Inc. - Future Price to Earnings|ANEW Medical, Inc. - Forward P/E Multiple|Market Cap to Projected Earnings NeuroSense Therapeutics NRSN|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|Projected Price to Earnings Ratio MetaVia (MTVA)|NRXS (NeurAxis) - Forward P/E Multiple|HSDT: Future Price to Earnings Multiple|Forward P/E Multiple PASG|Forward P/E Multiple bionomics.com.au (NEUP)|Minerva Neurosciences - Projected Price to Earnings|athira.com - Future Price to Earnings|Addex Therapeutics Ltd - Forward P/E Multiple|Projected Price to Earnings Ratio Alzamend Neuro, Inc.|cyclerion.com (CYCN) - Future Price to Earnings|Price to Future Earnings Ratio PTIX|Projected Price to Earnings KTTA|CRGT: Future Price to Earnings Multiple|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|Future Price to Earnings BCLI (Brainstorm Cell Therapeutics Inc.)|Cara Therapeutics, Inc - Projected Price to Earnings|Market Cap to Future Earnings Ratio CHRO (Chromocell)|Eliem - Forward P/E Multiple|ITCI (Intra-Cellular Therapies) - Price to Future Earnings Ratio|LBPH (Longboard Pharmaceuticals, Inc.) - Projected Price to Earnings|MRNS - Market Cap to Projected Earnings|NKGN (NKGen) - Forward P/E Multiple|Future Price to Earnings NRBO|Forward P/E Multiple SAGE|SNPX (synaptogen.com) - Future Price to Earnings Multiple|Trevena - Projected Price to Earnings|Vigil Neuroscience Inc. - Future Price to Earnings|WENA - Future Price to Earnings|CERE (Cerevel Corp) - Price to Future Earnings Ratio
